Financial Health Of Merck Side 1 af 2 Merck and Co., Inc. appears to be a continued uprising pharmaceutical company but only financial ratios can determine what their financial situation truly is. In looking at company evaluation, the last two annual reports from previous years should be carefully analyzed before making any major decisions. Since Merck is a pharmaceutical company, it would probably be an excellent idea to compare this company to another in the same industry. Company Background
Words: 1136 - Pages: 5
many factors a business, such as Merck, must have in order to be successful, for example strong financial statements, leading technology, and globalization. With the help of income statements, balance sheets, and cash flow statements, a financial analysis can be applied in a wide variety of situations to give business managers the information they need to make critical decisions (Financial Analysis, 2010). They also provide information in regards to the financial health of a company. Pharmaceutical
Words: 2950 - Pages: 12
Executive Summary The pharmaceutical company Merck has traditionally sold medicines and products that have been developed through its internal research. So, it is not surprising to see that the company spends quite a large amount of money on research. This is reflected in its financial statement as given in the exhibit 1. The R&D expenditure is about 7% of Merck’s revenues. The life cycle of a drug takes it from the research labs to three phases of testing, each increasingly complex, then through
Words: 3097 - Pages: 13
Risk Analysis Debt to equity is a measure of a company’s financial leverage. It indicates what proportion of equity and debt the company is using to finance its assets. From 2010 to 2012, the total debt/equity ratios of Merck & Co. went from 0.33 to 0.32 and 0.39. Although the ratio didn’t change dramatically from 2010 to 2011, it did increase incredibly during year 2012. It shows that Merck & Co. had been aggressive in financing its growth with debt. The increasing debt/equity ratio means
Words: 799 - Pages: 4
dilemma, the only viable uses for the drug would be for people who living in some of the poorest countries in the world; how could Merck underwrite the development of such a product for which there would most likely be of no economic value? On average it takes 12 years of research and development to bring a drug to market and costs in the neighborhood of $200 million. Merck would likely never recoup this investment cost and it would never be a profitable product. However, there would not be a lack
Words: 2332 - Pages: 10
Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23, 2011 DeVry University Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United
Words: 2468 - Pages: 10
Executive Summary The pharmaceutical company Merck has traditionally sold medicines and products that have been developed through its internal research. So, it is not surprising to see that the company spends quite a large amount of money on research. This is reflected in its financial statement as given in the exhibit 1. The R&D expenditure is about 7% of Merck's revenues. The life cycle of a drug takes it from the research labs to three phases of testing, each increasingly complex, then through
Words: 1229 - Pages: 5
valuation. The method used has to be objective and valid. This case study is about LAB and its decision to license off Davanrik to Merck. This analysis is about how Merck has been able to generate substantial returns given the costly and lengthy time to develop drugs and the potential outcome for Davanrik should LAB licenses off to Merck, Also, the analysis will determine if Merck should license the drug and for how much, and to determine how much LAB would receive given a 5% royalty fee on any cash flow
Words: 963 - Pages: 4
Merck & Medco You Decide Assignment Merck’s acquisition of Medco: Merger Analysis and Recommendation by Marzena Porebski . Table of Contents 1.0 INTRODUCTION 2 2.0 THE COMPANY OVERVIEW 3 2.1 Merck & Company 3 2.2 Medco Containment Services Inc. 5 2.3 The Companies Advantages 6 3.0 MERCK & MEDCO MERGER 7 3.1 Acquisition Details 7 3.2 Merger Analysis 7 4.0 CONCLUSION 11 5.0 APPENDIX 12 5.1 Financial Reports 12 5.2 Sales of Drugs and Prices 13 5.3 Merger and Acquisition
Words: 3006 - Pages: 13
9-201-023 REV: MARCH 25, 2003 RICHARD S. RUBACK Merck & Company: Evaluating a Drug Licensing Opportunity Rich Kender, Vice President of Financial Evaluation & Analysis at Merck, was working with his team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound
Words: 2603 - Pages: 11
